Abstract

Abstract

Introduction: Calcitonin (Ct) and carcinoembrional antigen (CEA) are widely used as tumor markers for the post-operative follow-up of patients with medullary thyroid carcinoma (MTC).

In patients with elevated serum Ct and CEA their dynamics can be described by calculating the doubling time (DT) - the time, they need to double the serum concentration. Previous reports concluded that the Ct and CEA DT have prognostic value in MTC patients.

Patients and methods: We retrospectively analyzed data of 70 MTC patients with elevated serum Ct or CEA. In total, doubling times were calculated and the DT of the less favorable marker was used to stratify the patients into the low- and high-risk group with the cut-off value of 2 years. The survival analysis was performed using Cox proportional hazard method.

Results: The doubling time < = 2 years of the less-favorable marker had significant prognostic impact for recurrence-free survival, HR = 2.61 (1.43-4.71) and overall survival, HR = 8.99 (3.51-23.04).

Conclusions: The calcitonin and carcinembrional antigen doubling times of less than two years are negative prognostic factors for MTC recurrence-free and total survival in patients with persistent or recurrent disease. They may be used as predictive factors for more intensive search of disease localization in asymptomatic hypercalcitoninemia and for therapy choice in symptomatic disease.

Details

Title
The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
Author
Gawlik, Tomasz; d'Amico, Andrea; Szpak-Ulczok, Sylwia; Skoczylas, Aleksander; Gubala, Elzbieta; Chorazy, Anna; Gorczewski, Kamil; Wloch, Jan; Jarzab, Barbara
First page
10
Publication year
2010
Publication date
2010
Publisher
BioMed Central
e-ISSN
1756-6614
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
902450686
Copyright
© 2010 Gawlik et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.